



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

CENTER FOR DRUG EVALUATION AND RESEARCH

Office of Manufacturing and Product Quality
Division of International Drug Quality
International Compliance Branch
10903 New Hampshire Avenue
Building #51, Room 4324
Silver Spring, MD 20993

TELEPHONE: (301) 796-3258
FAX: (301) 847-8742

July 22, 2011

Mr. Ing. Daniel Haymann
C.E.O. and President
Laboratorios Haymann S.A.
Gianelli 1489
Montevideo
Uruguay

FEI: 3004000118

Dear Mr. Haymann:

We have completed our review of the Establishment Inspection Report (EIR) for the inspection conducted at your finished dosage and active pharmaceutical ingredient manufacturing facility in Montevideo, Uruguay by FDA Investigator Ernest Bizjak, during the period of May 16-19, 2011. An FDA-483, Notice of Inspectional Observations was issued at the conclusion of the inspection.

We have also reviewed your company's response dated June 24, 2011 with supportive documentation. Based on the inspection, we are classifying your facility as acceptable. This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to assure continued compliance with current good manufacturing practices (CGMPs).

Additionally, we enclose a copy of the establishment inspection report (EIR). Releasing this EIR to you is part of FDA's effort to make its regulatory process and activities more transparent to the regulated industry. It is being provided to you for information purposes only and may reflect some redactions made by FDA in accordance with the FOIA and C.F.R. Part 20. Copies provided to other requestors may have additional redactions of trade secret and confidential commercial information.

If you have any questions regarding this letter, you may contact me at the above address or telephone number.

Sincerely,

Steven Thurber
Consumer Safety Officer
International Compliance Branch

Enclosure: EIR